SAN CARLOS, Calif. — May 5, 2026 — Leads & Copy —
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, scheduled for June 5–8, 2026, in New Orleans.
The presentations will feature data from icovamenib, the company’s investigational oral menin inhibitor, across both type 1 and type 2 diabetes. The data highlights the potential of icovamenib to improve beta cell function and support metabolic health.
One presentation will detail glycemic improvements with icovamenib in T2D on background GLP-1 therapy, based on a COVALENT-111 subgroup analysis. Juan Pablo Frías, M.D., will present this data on June 7, 2026, from 12:30 pm to 1:30 pm CT, during Late-Breaking Poster Session 2857-LB.
Another presentation will focus on how icovamenib, a menin inhibitor, improves endogenous insulin secretion in Type 1 diabetes, based on results from the COVALENT-112 study. Dr. Frias will also present this poster, designated Late-Breaking Poster Session 2858-LB, on June 7, 2026, from 12:30 pm to 1:30 pm CT.
The third presentation will outline how menin inhibitor icovamenib activates mechanisms that support metabolic health. Mini Balakrishnan, Ph.D., will present this information during Late-Breaking Poster Session 2871-LB on June 7, 2026, from 12:30 pm to 1:30 pm CT.
All presentation materials will be available on the Diabetes® journal website and in the Investors & Media section of Biomea’s website following the lifting of the embargo on Friday, June 5, 2026, at 6:30 PM CT.
Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of diabetes. It targets menin, a transcriptional regulator implicated in beta cell dysfunction. Preclinical and clinical studies have shown that icovamenib induces transient reductions in menin protein levels in pancreatic islets, thereby modulating pathways associated with insulin secretion and glycemic control.
Through this mechanism, icovamenib has the potential to restore beta cell mass and function and improve endogenous insulin production. As a potential short-course therapy, icovamenib could represent a novel treatment approach for patients with diabetes, particularly those who have not achieved adequate control with standard-of-care therapies.
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions.
We aim to cure.
Source: Biomea Fusion
